New York: In 2006, five-and-a-half percent of all global pharma patent applications listed one or more inventors from India, a fourfold jump from 1995.
India is emerging as a destination for high value R&D alongside the lower value manufacturing and clinical trial work for western pharmaceutical giants, says a study by US based academic Vivek Wadhwa.
“The Indian companies are really, really smart. They are looking at a very large generics market but they have also realised that they can now become the R&D capital of the world, so what they are doing now is they are looking for opportunities to assist American big pharma in developing sophisticated new drugs and also they are doing their own drug discovery,” he says.
The study found China leads India as the preferred destination for clinical trials, animal experimentation and manufacturing. But India is seen as a better venue for chemistry and drug discovery activities.
China produces 10 times as many Ph Ds in science and engineering as India.
But as Indian companies have the most experience in selling generic drugs that meet FDA standards, India is playing a bigger role for western companies in drug research and development and could soon emerge as a major powerhouse in its own right.
Comments
0 comment